Phase 1
N=15
A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma
Lymphoma, Follicular
Bottom Line
View on ClinicalTrials.gov: NCT00315731 ↗Enrolled (actual)
15
Serious AEs
26.7%
Results posted
Apr 2012
Primary outcome: Primary: Area Under the Curve (AUC) at 0 to 120, 0 to 168, and 0 to Infinity Hours — 1.04; 1.18; 1.39 %ID.h/mL
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- Follicular Lymphoma (Biological)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- GlaxoSmithKline
- Primary completion
- Dec 2006
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Area Under the Curve (AUC) at 0 to 120, 0 to 168, and 0 to Infinity Hours |
1.04; 1.18; 1.39 | — |
| PRIMARY Maximum Concentration (Cmax) Values |
0.0189; 0.0193 | — |
| PRIMARY Terminal Phase Half-life (t½) |
59.5 | — |
| PRIMARY Clearance (CL) Values |
71.9 | — |
| PRIMARY Volume of Distribution at Steady State (Vss) |
6055 | — |
| SECONDARY Area Under the Curve (AUC) at 0 to 120 Hours |
1.04; 1.07 | — |
| SECONDARY Area Under the Curve (AUC) at 0 to 168 Hours |
1.18; 1.24 | — |
| SECONDARY Area Under the Curve (AUC) at 0 to Infinity (Extrapolated) |
1.39; 1.50 | — |
| SECONDARY Maximum Concentration (Cmax) Values |
0.0189; 0.0193 | — |
| SECONDARY Mean Residence Times From Day 0 to Day 7 |
87.9; 95.7; 1.5; 1.9; 3.7; 4.7 | — |
| SECONDARY Mean Absorbed Dose in the Source Organs and the Target Organs |
0.23; 0.25; 0.25; 0.28; 0.19; 0.2 | — |
| SECONDARY Number of Participants With Expected Distribution of Radioactivity in the Circulatory System Compared With Uptake by Other Organs. |
10; 22 | — |
| SECONDARY Percentage of Participants Evaluable for Confirmed Response With Complete Response (CR), CR Unconfirmed (CRu), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD) |
67; 33; 7; 7; 27; 7 | — |
| SECONDARY Duration of Response |
NA | — |
| SECONDARY Progression-free Survival |
59.0 | — |
| SECONDARY Overall Survival |
NA | — |
Summary
Patients will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I 131 Tositumomab. Pharmacokinetic data for the primary endpoint analysis will be derived from testing done on blood samples drawn at 12 timepoints over the first 7 days following administration of the dosimetric dose. Whole body gamma camera images will be obtained on six days following the dosimetric dose. Organ and tumor dosimetry data will be generated from gamma camera counts of specific organs and tumor. All scans will be examined by an independent review panel to evaluate biodistribution of the radionuclide.
Using the dosimetric data from three of the six imaging time points and the patient's weight, a patient-specific activity (mCi) of Iodine-131 will be calculated to deliver the desired total body dose of radiation (75 cGy). Patients will receive an infusion of unlabeled Tositumomab (450 mg) immediately followed by an infusion of the patient specific dose of tellurium-derived Iodine I 131 Tositumomab (35 mg) to deliver a total body dose (TBD) of 75 cGy. Patients will be followed closely obtaining safety information during the post-treatment period, and for response and safety at 3,6,and 12 months during the first year, annually thereafter up to five years, and annually for additional safety and outcomes information up to 10 years.
Eligibility Criteria
Inclusion criteria
- At least 18 years of age
- A histologically confirmed diagnosis of the following:
Follicular lymphoma, Grade 1, 2, or 3 or diffuse large cell lymphoma concurrent with or following the diagnosis of follicular lymphoma (World Health Organization/Revised European-American Lymphoma [WHO/REAL] classification).
International Working Formulation histological equivalents included:
Follicular, small-cleaved; Follicular, mixed small-cleaved and large-cell; Follicular large-cell; or Transformed diffuse large-cell lymphoma following or concurrent with a diagnosis of follicular lymphoma.
- Stage III or IV disease at the time of study entry (based on Ann Arbor Staging Classification)
- Previously untreated or recurrent lymphoma after no more than 4 prior qualifying therapy regimens; steroids alone, as treatment for lymphoma, not considered a treatment regimen
- Performance status of at least 70% on the Karnofsky Performance Scale and an anticipated survival of at least 3 months.
- Bi dimensionally measurable disease with at least one lesion measuring greater than or equal to 2.0 cm x 2.0 cm (greater than or equal to 4.0 cm2) by computed tomography (CT) scan
- Absolute B lymphocyte count (as determined by CD19 reactivity [flow cytometric determination of CD19+ B lymphocyte count]) of 30 to 350 cell/mm3 within 21 days prior to study enrollment
- Absolute neutrophil count greater than or equal to 1500 cells/mm3; platelet count greater than or equal to 150,000/mm3; and hemoglobin greater than or equal to 10 g/dL within 21 days prior to study enrollment; blood products and/or growth factors not taken within 4 weeks prior to blood draw
- Adequate renal function, defined as serum creatinine <1.5 x upper limit of normal (ULN), and hepatic function, defined as total bilirubin <1.5 x ULN and aspartate transaminase (AST) <5 x ULN, within 21 days of study enrollment
- HAMA negative within 21 days prior to study enrollment
- Signed IRB approved consent form prior to any study-specific procedures being implemented
Exclusion criteria
- Greater than 25% of the intratrabecular marrow space involved by lymphoma in bone marrow biopsy specimens as assessed microscopically within 90 days of study enrollment; a unilateral bone marrow biopsy was adequate; marrow core was greater than or equal to 2.0 cm in length
- Prior chemotherapy, biologic therapy, steroids, or radiation therapy as treatment for NHL within 28 days prior to study enrollment; subjects receiving low doses of steroids for non neoplastic disease acceptable to enter this study ("Low dose steroids" was defined as less than or equal to 10 mg of prednisone or equivalent per day.)
- Prior rituximab therapy within 120 days prior to study enrollment
- Prior radioimmunotherapy
- Prior splenectomy
- Splenomegaly defined as spleen mass greater than 700 grams, where splenic mass was defined as follows:
Spleen mass = л(X x Y x Z)/6 Where X and Y are the greatest perpendicular diameters in cm on any single CT scan slice, and Z is the number of CT scan slices upon which the spleen is visible times the slice thickness in cm
- Bulky disease as defined as any uni-dimensional measurement of lymphomatous mass exceeding 7 cm
- Prior malignancy other than lymphoma, except for adequately treated skin cancer, in situ cervical cancer, or other cancer for which the subject had a generally accepted risk of recurrence less than 20%
- Central nervous system involvement by lymphoma
- Evidence of active infection requiring IV antibiotics at the time of study enrollment
- Known human immunodeficiency virus (HIV) infection
- New York Heart Association Class III or IV heart disease or other serious illness that would preclude evaluation.
- Active obstructive hydronephrosis
- Evidence of clinically significant ascites or pleural effusion observed on screening physical examination or baseline CT scan
- Prior myeloablative therapy
- History of failed stem cell collection
Data sourced from ClinicalTrials.gov (NCT00315731). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.